170 related articles for article (PubMed ID: 25428390)
1. Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia.
Zhou JD; Yang L; Zhang YY; Yang J; Wen XM; Guo H; Yao DM; Ma JC; Chen Q; Lin J; Qian J
Med Oncol; 2015 Jan; 32(1):386. PubMed ID: 25428390
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia.
Zhou JD; Yang L; Zhu XW; Wen XM; Yang J; Guo H; Chen Q; Yao DM; Ma JC; Lin J; Qian J
Int J Clin Exp Pathol; 2015; 8(5):5336-44. PubMed ID: 26191235
[TBL] [Abstract][Full Text] [Related]
3. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Langer C; Radmacher MD; Ruppert AS; Whitman SP; Paschka P; Mrózek K; Baldus CD; Vukosavljevic T; Liu CG; Ross ME; Powell BL; de la Chapelle A; Kolitz JE; Larson RA; Marcucci G; Bloomfield CD;
Blood; 2008 Jun; 111(11):5371-9. PubMed ID: 18378853
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CTNNB1: Clinical implication in Chinese de novo acute myeloid leukemia.
Li XX; Guo H; Zhou JD; Wu DH; Ma JC; Wen XM; Zhang W; Xu ZJ; Lin J; Jun Q
Pathol Res Pract; 2018 Mar; 214(3):361-367. PubMed ID: 29496308
[TBL] [Abstract][Full Text] [Related]
5. High expression of dual-specificity phosphatase 5 pseudogene 1 (DUSP5P1) is associated with poor prognosis in acute myeloid leukemia.
Zhou LY; Yin JY; Tang Q; Zhai LL; Zhang TJ; Wang YX; Yang DQ; Qian J; Lin J; Deng ZQ
Int J Clin Exp Pathol; 2015; 8(12):16073-80. PubMed ID: 26884884
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
7. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
8. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
[TBL] [Abstract][Full Text] [Related]
9. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.
Jentzsch M; Bill M; Grimm J; Brauer D; Backhaus D; Goldmann K; Schulz J; Niederwieser D; Platzbecker U; Schwind S
Ann Hematol; 2020 Oct; 99(10):2417-2427. PubMed ID: 32862286
[TBL] [Abstract][Full Text] [Related]
11. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Schwind S; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Holland KB; Margeson D; Becker H; Whitman SP; Wu YZ; Metzeler KH; Powell BL; Kolitz JE; Carter TH; Moore JO; Baer MR; Carroll AJ; Caligiuri MA; Larson RA; Bloomfield CD
Blood; 2010 Dec; 116(25):5660-9. PubMed ID: 20841507
[TBL] [Abstract][Full Text] [Related]
12. BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.
Niu Y; Yang X; Chen Y; Zhang L; Jin X; Tang Y; Li L; Yu L; Guo Y; Wang H
Pathol Oncol Res; 2019 Apr; 25(2):541-548. PubMed ID: 30357752
[TBL] [Abstract][Full Text] [Related]
13. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
14. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
[TBL] [Abstract][Full Text] [Related]
15. Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia.
Yang DQ; Zhou JD; Wang YX; Deng ZQ; Yang J; Yao DM; Qian Z; Yang L; Lin J; Qian J
Int J Lab Hematol; 2017 Feb; 39(1):42-50. PubMed ID: 27577964
[TBL] [Abstract][Full Text] [Related]
16. BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia.
Zhou JD; Yang J; Guo H; Deng ZQ; Wen XM; Yang L; Yin JY; Xiao GF; Lin J; Qian J
Leuk Lymphoma; 2016; 57(4):828-34. PubMed ID: 26325005
[TBL] [Abstract][Full Text] [Related]
17. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
[TBL] [Abstract][Full Text] [Related]
18. Relation of BAALC and ERG Gene Expression with Overall Survival in Acute Myeloid Leukemia Cases.
Rashed RA; Kadry DY; El Taweel M; Abd El Wahab N; Abd El Hameed T
Asian Pac J Cancer Prev; 2015; 16(17):7875-82. PubMed ID: 26625814
[TBL] [Abstract][Full Text] [Related]
19. Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia.
Najima Y; Ohashi K; Kawamura M; Onozuka Y; Yamaguchi T; Akiyama H; Sakamaki H
Int J Hematol; 2010 May; 91(4):636-45. PubMed ID: 20376583
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
Mizushima Y; Taki T; Shimada A; Yui Y; Hiraumi Y; Matsubara H; Watanabe M; Watanabe K; Kamitsuji Y; Hayashi Y; Tsukimoto I; Kobayashi R; Horibe K; Tawa A; Nakahata T; Adachi S
Int J Hematol; 2010 Jun; 91(5):831-7. PubMed ID: 20495894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]